Tandem Diabetes Care, Inc.
Financials
Valuation Metrics
Tandem Diabetes Care, Inc.'s Market Cap is $1.38B. At end of 2025 it was $1.49B. Ranked #2306 of 3,111 in US market (top 74%), #919 of 1,445 on NASDAQ (top 64%), #140 of 206 in Health Care Equipment & Services (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.38B | US#2,306/3,111 Sec#140/206 |
| Revenue | $1.03B | US#1,925/3,111 Sec#116/206 |
| Net Income | $-95M | US—/3,111 Sec—/206 |
| Total Assets | $1.15B | US#2,402/3,111 Sec#123/206 |
| Net Assets | $132M | US#2,843/3,111 Sec#183/206 |
| Employees | 2,500 | US#1,056/3,111 Sec#88/206 |
| Value | ||
| P/B | 10.41x | US#2,629/3,111 Sec#174/206 |
| P/S | 1.34x | US#864/3,111 Sec#60/206 |
| FCF Yield | -0.26% | US—/3,111 Sec—/206 |
| Profitability | ||
| ROE | -71.41% | US#2,810/3,111 Sec#179/206 |
| ROA | -8.20% | US#2,623/3,111 Sec#151/206 |
| Op. Margin | -7.88% | US#2,617/3,111 Sec#155/206 |
| Revenue Growth | 5.46% | US#1,703/3,111 Sec#126/206 |
| Financial Health | ||
| Debt Ratio | 771.12% | US#2,612/3,111 Sec#194/206 |
| Total Debt | $735M | US#1,657/3,111 Sec#89/206 |
| FCF | $-4M | US#2,299/3,111 Sec#151/206 |
| Cash | $179M | US#1,807/3,111 Sec#109/206 |
| Current Ratio | 3.58x | US#645/3,111 Sec#67/206 |
| Performance | ||
| 1Y Return | 30.58% | US#1,297/3,111 Sec#86/206 |
| 1M Return | 31.27% | US#90/3,111 Sec#14/206 |
| From 52W High | -32.18% | US#2,277/3,111 Sec#153/206 |
| 1Y MDD | -56.97% | US#2,644/3,111 Sec#161/206 |
| Trading | ||
| Volume | 3,294,526 shares | US#911/3,111 Sec#52/206 |
| Trading Value | $66M | US#1,576/3,111 Sec#106/206 |
| Per Share | ||
| EPS | $-3.01 | US—/3,111 Sec—/206 |
| BPS | $2.28 | US#2,484/3,111 Sec#169/206 |
Company Info
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.